We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

QUINENCO:BCSQuinenco S.A. Analysis

Data as of 2026-03-16 - not real-time

CLP 4,332.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Quiñenco SA trades at 4,332 CLP, comfortably above its 20‑day SMA (4,291) but just under the 50‑day SMA (4,421), indicating short‑term strength while still respecting a broader neutral trend. The RSI sits at 51, suggesting the stock is neither overbought nor oversold, and the MACD histogram has turned positive with a bullish signal line crossover, reinforcing modest upside momentum. Volume is on the rise, and the price remains comfortably above the identified support at 4,076 CLP, with resistance near 4,453 CLP, offering a clear upside corridor.
Fundamentally, the stock appears undervalued: a trailing P/E of 8.73 versus an industry average of 22.28, a P/B of 0.79, and a dividend yield of 6.99% with a 73% payout ratio supported by strong operating and free cash flow. However, the balance sheet is heavily leveraged (debt‑to‑equity ≈ 105%) despite sizable cash reserves, and the 30‑day volatility of 26% combined with a low beta (0.18) points to modest market sensitivity but heightened company‑specific risk. The DCF‑derived fair value suggests a target around 5,200 CLP, implying roughly 20% upside, while the Fear & Greed Index registers “Extreme Greed,” hinting at bullish sentiment in the market.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD histogram with signal crossover
  • Increasing trading volume
  • Price above 20‑day SMA and support level

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Low P/E relative to industry peers
  • High dividend yield with sustainable payout
  • Target price offering ~20% upside

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong operating and free cash flow generation
  • Elevated debt‑to‑equity ratio creating balance‑sheet risk
  • Consistent dividend policy supporting income investors

Key Metrics & Analysis

Financial Health

Revenue Growth2.40%
Profit Margin9.38%
P/E Ratio8.7
ROE11.68%
ROA1.56%
Debt/Equity104.65
P/B Ratio0.8
Op. Cash FlowCLP2298.8B
Free Cash FlowCLP2273.3B
Industry P/E22.3

Technical Analysis

TrendNeutral
RSI51.2
SupportCLP 4,076.20
ResistanceCLP 4,453.10
MA 20CLP 4,291.11
MA 50CLP 4,420.53
MA 200CLP 4,160.31
MACDBullish
VolumeIncreasing
Fear & Greed Index77.96

Valuation

Fair ValueCLP 11,884.61
Target PriceCLP 5,200.00
Upside/Downside20.04%
GradeUndervalued
TypeValue
Dividend Yield6.99%

Risk Assessment

Beta0.18
Volatility25.98%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.